Advertisement
Screener

ANIXA BIOSCIENCES, INC. (ANIX) Selling, General and Administrative Expense

2.8 / 5 stars · 68/120 Roast Me

ANIXA BIOSCIENCES, INC. Selling, General and Administrative Expense

ANIXA BIOSCIENCES, INC. (ANIX) reported Selling, General and Administrative Expense of $1.44 million for the 3-month period ending 2020-04-30, per its 10-Q filed 2020-06-09.

Discontinued › Expense Statement › Operating Expenses

us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2020-06-09

  • ANIXA BIOSCIENCES, INC. selling, general and administrative expense for the quarter ending 2020-04-30 was $1.44M, a 12.43% increase year-over-year.
  • ANIXA BIOSCIENCES, INC. selling, general and administrative expense for the quarter ending 2020-01-31 was $1.14M, a 44.87% decline year-over-year.
  • ANIXA BIOSCIENCES, INC. selling, general and administrative expense for the quarter ending 2019-10-31 was $1.26M, a 45.55% decline year-over-year.
  • ANIXA BIOSCIENCES, INC. selling, general and administrative expense for the quarter ending 2019-07-31 was $1.06M, a 60.91% decline year-over-year.
  • ANIXA BIOSCIENCES, INC. selling, general and administrative expense for fiscal 2019 was $5.66M, a 18.07% decline from fiscal 2018.
  • ANIXA BIOSCIENCES, INC. selling, general and administrative expense for fiscal 2018 was $6.91M, a 56.71% increase from fiscal 2017.
  • ANIXA BIOSCIENCES, INC. selling, general and administrative expense for fiscal 2017 was $4.41M, a 62.77% increase from fiscal 2016.
  • ANIXA BIOSCIENCES, INC. selling, general and administrative expense for fiscal 2016 was $2.71M, a 50.86% decline from fiscal 2015.
Period endSelling, General and Administrative Expense 3 monthSelling, General and Administrative Expense 3 month as first filedSelling, General and Administrative Expense 6 monthSelling, General and Administrative Expense 6 month as first filedSelling, General and Administrative Expense 9 monthSelling, General and Administrative Expense 9 month as first filedSelling, General and Administrative Expense 12 monthSelling, General and Administrative Expense 12 month as first filed
2020-04-30$1.44M
10-Q · filed 2020-06-09
$2.58M
10-Q · filed 2020-06-09
$3.84M
derived: sum of 3 quarters · filed 2020-06-09
$4.90M
derived: sum of 4 quarters · filed 2020-06-09
2020-01-31$1.14M
10-Q · filed 2020-03-09
$2.40M
derived: sum of 2 quarters · filed 2020-03-09
$3.45M
derived: sum of 3 quarters · filed 2020-03-09
$4.74M
derived: sum of 4 quarters · filed 2020-06-09
2019-10-31$1.26M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-01-09
$2.31M
derived: sum of 2 quarters · filed 2020-01-09
$3.60M
derived: sum of 3 quarters · filed 2020-06-09
$5.66M
10-K · filed 2020-01-09
2019-07-31$1.06M
10-Q · filed 2019-09-06
$2.34M
derived: sum of 2 quarters · filed 2020-06-09
$4.41M
10-Q · filed 2019-09-06
$6.71M
derived: sum of 4 quarters · filed 2020-06-09
2019-04-30$1.28M
10-Q · filed 2020-06-09
$3.35M
10-Q · filed 2020-06-09
$5.66M
derived: sum of 3 quarters · filed 2020-06-09
$8.36M
derived: sum of 4 quarters · filed 2020-06-09
2019-01-31$2.07M
10-Q · filed 2020-03-09
$4.38M
derived: sum of 2 quarters · filed 2020-03-09
$7.08M
derived: sum of 3 quarters · filed 2020-03-09
$7.99M
derived: sum of 4 quarters · filed 2020-03-09
2018-10-31$2.31M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-01-09
$5.01M
derived: sum of 2 quarters · filed 2020-01-09
$5.92M
derived: sum of 3 quarters · filed 2020-01-09
$6.91M
10-K · filed 2020-01-09
2018-07-31$2.70M
10-Q · filed 2019-09-06
$3.61M
derived: sum of 2 quarters · filed 2019-09-06
$4.60M
10-Q · filed 2019-09-06
$5.95M
derived: sum of 4 quarters · filed 2019-09-06
2018-04-30$908.77K
10-Q · filed 2019-06-12
$1.90M
10-Q · filed 2019-06-12
$3.24M
derived: sum of 3 quarters · filed 2019-06-12
$4.75M
derived: sum of 4 quarters · filed 2019-06-12
2018-01-31$990.04K
10-Q · filed 2019-03-13
$2.33M
derived: sum of 2 quarters · filed 2019-03-13
$3.84M
derived: sum of 3 quarters · filed 2019-03-13
$4.54M
derived: sum of 4 quarters · filed 2019-03-13
2017-10-31$1.34M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-01-11
$2.85M
derived: sum of 2 quarters · filed 2019-01-11
$3.55M
derived: sum of 3 quarters · filed 2019-01-11
$4.41M
10-K · filed 2019-01-11
2017-07-31$1.51M
10-Q · filed 2018-09-07
$1.51M
10-Q · filed 2017-09-08
$2.21M
derived: sum of 2 quarters · filed 2018-09-07
$3.07M
10-Q · filed 2018-09-07
$3.61M
derived: sum of 4 quarters · filed 2018-09-07
2017-04-30$699.35K
10-Q · filed 2018-06-11
$1.56M
10-Q · filed 2018-06-11
$2.11M
derived: sum of 3 quarters · filed 2018-06-11
$2.74M
derived: sum of 4 quarters · filed 2018-06-11
2017-01-31$859.88K
10-Q · filed 2018-03-09
$1.41M
derived: sum of 2 quarters · filed 2018-03-09
$2.04M
derived: sum of 3 quarters · filed 2018-03-09
$2.70M
derived: sum of 4 quarters · filed 2018-03-09
2016-10-31$546.51K
derived: 10-K 12 month − 10-Q 9 month · filed 2018-01-09
$1.18M
derived: sum of 2 quarters · filed 2018-01-09
$1.84M
derived: sum of 3 quarters · filed 2018-01-09
$2.71M
10-K · filed 2018-01-09
2016-07-31$631.23K
10-Q · filed 2017-09-08
$923.29K
10-Q · filed 2016-08-19
$1.29M
derived: sum of 2 quarters · filed 2017-09-08
$2.16M
10-Q · filed 2017-09-08
$3.31M
10-Q · filed 2016-08-19
$2.53M
derived: sum of 4 quarters · filed 2017-09-08
2016-04-30$658.95K
10-Q · filed 2017-05-26
$1.05M
10-Q · filed 2016-05-20
$1.53M
10-Q · filed 2017-05-26
$2.38M
10-Q · filed 2016-05-20
$1.89M
derived: sum of 3 quarters · filed 2017-05-26
$3.32M
derived: sum of 4 quarters · filed 2017-05-26
2016-01-31$873.42K
10-Q · filed 2017-03-16
$1.33M
10-Q · filed 2016-02-19
$1.24M
derived: sum of 2 quarters · filed 2017-03-16
$2.66M
derived: sum of 3 quarters · filed 2017-03-16
$4.61M
derived: sum of 4 quarters · filed 2017-03-16
2015-10-31$362.07K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-12-08
$1.78M
derived: sum of 2 quarters · filed 2016-12-08
$3.74M
derived: sum of 3 quarters · filed 2016-12-08
$5.51M
10-K · filed 2016-12-08
$6.23M
10-K · filed 2015-12-23
2015-07-31$1.42M
10-Q · filed 2016-08-19
$3.38M
derived: sum of 2 quarters · filed 2016-08-19
$5.15M
10-Q · filed 2016-08-19
$6.75M
derived: sum of 4 quarters · filed 2016-08-19
2015-04-30$1.96M
10-Q · filed 2016-05-20
$3.73M
10-Q · filed 2016-05-20
$5.33M
derived: sum of 3 quarters · filed 2016-05-20
$6.43M
derived: sum of 4 quarters · filed 2016-05-20
2015-01-31$1.77M
10-Q · filed 2016-02-19
$3.38M
derived: sum of 2 quarters · filed 2016-02-19
$4.48M
derived: sum of 3 quarters · filed 2016-02-19
$6.32M
derived: sum of 4 quarters · filed 2016-02-19
2014-10-31$1.60M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-23
$2.70M
derived: sum of 2 quarters · filed 2015-12-23
$4.55M
derived: sum of 3 quarters · filed 2015-12-23
$6.41M
10-K · filed 2015-12-23
2014-07-31$1.10M
10-Q · filed 2015-08-18
$2.95M
derived: sum of 2 quarters · filed 2015-08-18
$4.81M
10-Q · filed 2015-08-18
$6.68M
derived: sum of 4 quarters · filed 2015-08-18
2014-04-30$1.84M
10-Q · filed 2015-05-22
$3.70M
10-Q · filed 2015-05-22
$5.57M
derived: sum of 3 quarters · filed 2015-05-22
$7.78M
derived: sum of 4 quarters · filed 2015-05-22
2014-01-31$1.86M
10-Q · filed 2015-03-09
$1.93M
10-Q · filed 2014-03-17
$3.73M
derived: sum of 2 quarters · filed 2015-03-09
$5.93M
derived: sum of 3 quarters · filed 2015-03-09
$7.78M
derived: sum of 4 quarters · filed 2015-03-09
2013-10-31$1.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-01-29
$4.07M
derived: sum of 2 quarters · filed 2015-01-29
$5.92M
derived: sum of 3 quarters · filed 2015-01-29
$7.99M
10-K · filed 2015-01-29
2013-07-31$2.20M
10-Q · filed 2014-09-15
$2.22M
10-Q/A · filed 2013-09-20
$4.05M
derived: sum of 2 quarters · filed 2014-09-15
$6.12M
10-Q · filed 2014-09-15
$6.12M
10-Q/A · filed 2013-09-20
$7.34M
derived: sum of 4 quarters · filed 2014-09-15
2013-04-30$1.84M
10-Q · filed 2014-06-16
$1.85M
10-Q/A · filed 2013-06-19
$3.92M
10-Q · filed 2014-06-16
$3.90M
10-Q/A · filed 2013-06-19
$5.14M
derived: sum of 3 quarters · filed 2014-06-16
$5.57M
derived: sum of 4 quarters · filed 2014-06-16
2013-01-31$2.07M
10-Q · filed 2014-03-17
$2.05M
10-Q/A · filed 2013-03-25
$3.29M
derived: sum of 2 quarters · filed 2014-03-17
$3.73M
derived: sum of 3 quarters · filed 2014-03-17
$4.25M
derived: sum of 4 quarters · filed 2014-03-17
2012-10-31$1.22M
derived: 10-K/A 12 month − 10-Q/A 9 month · filed 2014-01-17
$1.66M
derived: sum of 2 quarters · filed 2014-01-17
$2.18M
derived: sum of 3 quarters · filed 2014-01-17
$2.86M
10-K/A · filed 2014-01-17
$2.87M
10-K · filed 2013-01-29
2012-07-31$433.68K
10-Q/A · filed 2013-09-20
$955.24K
derived: sum of 2 quarters · filed 2013-09-20
$1.64M
10-Q/A · filed 2013-09-20
$2.36M
derived: sum of 4 quarters · filed 2013-09-20
2012-04-30$521.56K
10-Q/A · filed 2013-06-19
$1.21M
10-Q/A · filed 2013-06-19
$1.93M
derived: sum of 3 quarters · filed 2013-06-19
$2.70M
derived: sum of 4 quarters · filed 2013-06-19
2012-01-31$686.03K
10-Q/A · filed 2013-03-25
$1.40M
derived: sum of 2 quarters · filed 2013-03-25
$2.18M
derived: sum of 3 quarters · filed 2013-03-25
$2.80M
derived: sum of 4 quarters · filed 2013-03-25
2011-10-31$718.87K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-01-29
$1.49M
derived: sum of 2 quarters · filed 2013-01-29
$2.11M
derived: sum of 3 quarters · filed 2013-01-29
$2.87M
10-K · filed 2013-01-29
2011-07-31$774.75K
10-Q · filed 2012-09-14
$1.39M
derived: sum of 2 quarters · filed 2012-09-14
$2.15M
10-Q · filed 2012-09-14
$2.80M
derived: sum of 4 quarters · filed 2012-09-14
2011-04-30$618.01K
10-Q · filed 2012-06-14
$1.38M
10-Q · filed 2012-06-14
$2.02M
derived: sum of 3 quarters · filed 2012-06-14
$2.64M
derived: sum of 4 quarters · filed 2012-06-14
2011-01-31$760.98K
10-Q · filed 2012-03-16
$1.40M
derived: sum of 2 quarters · filed 2012-03-16
$2.02M
derived: sum of 3 quarters · filed 2012-03-16
2010-10-31$643.05K
derived: 10-K 12 month − 10-Q/A 9 month · filed 2012-01-30
$1.26M
derived: sum of 2 quarters · filed 2012-01-30
$2.89M
10-K · filed 2012-01-30
2010-07-31$620.97K
10-Q/A · filed 2011-10-14
$2.25M
10-Q/A · filed 2011-10-14

Similar stocks

Stock NameCountryMarket CapPE Ratio
CITIUS ONCOLOGY, INC. (CTOR)United States$0.097B-1.49
Milestone Pharmaceuticals Inc. (MIST)$0.098B-2.00
Acrivon Therapeutics, Inc. (ACRV)United States$0.091B-1.03
ProMIS Neurosciences Inc. (PMN)$0.102B
Rallybio Corp (RLYB)United States$0.089B
Polaryx Therapeutics, Inc. (PLYX)United States$0.106B
ONCOLYTICS BIOTECH INC (ONCY)$0.086B
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)United States$0.086B
Biomea Fusion, Inc. (BMEA)United States$0.107B-3.30
Lexaria Bioscience Corp. (LEXX)$0.084B-1.92